 |
|
|
| |
All-Oral Treatment with Daclatasvir Plus Sofosbuvir ± Ribavirin in HCV Genotype 3-Infected Patients With Advanced Fibrosis or Cirrhosis:
An Analysis of ALLY-3 and ALLY-3+
|
| |
| |
Reported by Jules Levin
EASL 2016 April 14-17 Barcelona
Kowdley KV,1 Angus P,2 Bernstein D,3 Bronowicki J-P,4 Leroy V,5 Pockros PJ,6 Bhore R,7 Rana K,8 Jimenez-Exposito MJ7
1Swedish Medical Center, Seattle, WA; 2Austin Hospital, Heidelberg, Australia; 3Hofstra North Shore-Long Island Jewish School of Medicine, Seattle, WA; 4CHU Nancy & Lorraine University, Nancy, France; 5CHU de Grenoble,
La Tronche, France; 6Scripps Clinic, La Jolla, CA; 7Bristol-Myers Squibb Research & Development, Princeton, NJ; 8Bristol-Myers Squibb Research & Development, Wallingford, CT
|
| |
|
|
|
|
|
